ASH 2018 | Aurora A kinase inhibitor alisertib and chemo is promising for untreated high-risk AML
Amir Fathi
• 6 Dec 2018
Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the Phase II trial of the Aurora A kinase inhibitor alisertib, combined with induction chemotherapy, in untreated high-risk acute myeloid leukemia (AML) patients (NCT02560025). This revealed an efficacious regimen, with promising remission and survival rates. This data was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
